Cargando…
Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index–Multimedia Version (ASI-MV)
BACKGROUND: Tapentadol is a molecule incorporating mu opioid receptor agonism and norepinephrine reuptake inhibition to provide analgesia, with the potential for a lower incidence of gastrointestinal side effects than full mu opioid agonists. Postmarketing surveillance of tapentadol as an active pha...
Autores principales: | Vosburg, Suzanne K, Beaumont, Jared, Dailey-Govoni, S Taryn, Butler, Stephen F, Green, Jody L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553020/ https://www.ncbi.nlm.nih.gov/pubmed/31617931 http://dx.doi.org/10.1093/pm/pnz250 |
Ejemplares similares
-
Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER
por: Geoffrey Severtson, Stevan, et al.
Publicado: (2020) -
Real-World Data on Nonmedical Use of Tramadol from Patients Evaluated for Substance Abuse Treatment in the NAVIPPRO Addiction Severity Index—Multimedia Version (ASI-MV(®)) Network
por: Green, Jody L., et al.
Publicado: (2020) -
Nonmedical Use of Xtampza(®) ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-World Data from the Addiction Severity Index-Multimedia Version (ASI-MV(®))
por: Green, Jody L, et al.
Publicado: (2021) -
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Chaves, Carolina, et al.
Publicado: (2020) -
Correlates of patterns of cannabis use, abuse and dependence: evidence from two national surveys in Ireland
por: Millar, Seán R, et al.
Publicado: (2021)